How much does a box of Sarilumab cost?

In placebo-controlled trials, in patients with an inadequate response to methotrexate or an inadequate response to or intolerance to at least one tumor necrosis factor (TNF) inhibitor, when combined with conventional synthetic DMARD (csDMARD) therapy When administered, Sarilumab improves the signs and symptoms of rheumatoid arthritis (RA), as well as physical function and health-related quality of life (HR-QOL). In open extensions, benefit duration is ≤3 years.

Salirumab plus methotrexate inhibits progression of structural damage in patients with poor response to methotrexate. As monotherapy, salivolumab was more effective than adalimumab in reducing signs and symptoms of RA and improving physical function as monotherapy in patients who were not candidates for continued methotrexate therapy. The safety profile of salirumab is consistent with the expected effects of IL-6 inhibition. In the small number of patients who test positive for anti-drug antibodies (ADAs), ADAs do not affect efficacy or increase adverse reactions. Therefore, salirumab expands available treatment options for adults with moderately to severely active RA who have an inadequate response to or intolerance to at least one DMARD.

The patent drug of Salirutumab is a new type of drug for treating diseases. It has not yet been launched in China, so it is not covered by medical insurance. Patients cannot yet purchase this drug in domestic hospitals or pharmacies. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.